Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report

Autor: Marie Karanian, Antoine Arnaud, Celine Mahier Ait Oukhatar, Alexandre Evrard, Morgane Broudic-Guibert, Rania Boustany-Grenier, Jean-Yves Blay, Léa Vazquez, N. Hoog-Labouret, Sophie Taïeb
Přispěvatelé: Institut Sainte Catherine [Avignon], Centre Léon Bérard [Lyon], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Division de la recherche et de l'innovation [Boulogne Billancourt] (INCa), Institut national du cancer [Boulogne] (INCA), UNICANCER [Paris], Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Université de Lille-UNICANCER
Rok vydání: 2019
Předmět:
Adult
Proto-Oncogene Proteins B-raf
Oncology
medicine.medical_specialty
Oral treatment
Lung Neoplasms
medicine.medical_treatment
Locally advanced
lcsh:Medicine
[SDV.CAN]Life Sciences [q-bio]/Cancer
030204 cardiovascular system & hematology
medicine.disease_cause
BRAF
Targeted therapy
Ameloblastoma
03 medical and health sciences
0302 clinical medicine
Surgical oncology
Internal medicine
Case report
medicine
Humans
Vemurafenib
Protein Kinase Inhibitors
Mutation
MESH: Lung Neoplasms / drug therapy
Lung Neoplasms / secondary
Lung Neoplasms / pahology
Protein Kinase Inhibitors / administration & dosage
business.industry
lcsh:R
General Medicine
[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences
medicine.disease
Jaw Neoplasms
3. Good health
Clinical trial
030220 oncology & carcinogenesis
Metastatic
Female
business
medicine.drug
Zdroj: Journal of Medical Case Reports
Journal of Medical Case Reports, BioMed Central, 2019, 13 (1), ⟨10.1186/s13256-019-2140-6⟩
Journal of Medical Case Reports, 2019, 13 (1), ⟨10.1186/s13256-019-2140-6⟩
Journal of Medical Case Reports, Vol 13, Iss 1, Pp 1-4 (2019)
ISSN: 1752-1947
DOI: 10.1186/s13256-019-2140-6
Popis: International audience; Ameloblastomas are uncommon locally aggressive tumors of odontogenic epithelium that rarely metastasize. Currently, there is no standard of care for the metastatic forms. Several studies have shown that ameloblastomas frequently have a BRAF mutation.Case presentation: We report a case of a 33-year-old Caucasian woman with ameloblastoma diagnosed 30 years ago who developed lung metastasis 19 years ago. Systemic oral treatment with vemurafenib, a BRAF inhibitor, was initiated 28 months ago within the AcSé French basket clinical trial of vemurafenib.Conclusions: The patient has shown a durable clinical, functional, and radiographic partial response with vemurafenib. These observations suggest the possibility of introducing neoadjuvant and/or adjuvant targeted therapy in locally advanced ameloblastoma to improve outcome. BRAF inhibition has proved to be an efficient strategy in patients with a BRAF-mutated ameloblastoma.
Databáze: OpenAIRE
Externí odkaz: